Pulmatrix

Specialty biotech developing the next generation of inhaled therapies for such conditions as #cysticfibrosis #COPD & idiopathic pulmonary fibrosis.

[Pulmatrix @Pulmatrix_Inc]

Pulmatrix Receives Orphan Drug Designation from FDA for Inhaled Drug to Treat Pulmonary Funga... https://t.co/VlXxA1afpQ via @YahooFinance

[Pulmatrix @Pulmatrix_Inc]

Pulmatrix and Mylan Report Positive Pharmacokinetic Bioavailability Data in Pilot Study of PUR0200 https://t.co/rB6onfbyDy

[Pulmatrix @Pulmatrix_Inc]

Advances in Inhaled Drug Delivery Offer Major Benefits to Patients, CSO for Pulmatrix Explains in Article https://t.co/gOZuVGeiVn

[Pulmatrix @Pulmatrix_Inc]

Capsugel and $PULM Enter Collaboration to Develop and Manufacture Novel Inhaled Therapeutics: https://t.co/TAWRZZF1DO

[Pulmatrix @Pulmatrix_Inc]

$PULM CEO Robert Clarke speaks with @healtheo360 about new treatments for #CysticFibrosis, #COPD and others: https://t.co/kHtGv57kz5

[Pulmatrix @Pulmatrix_Inc]

$PULM CEO Bob Clarke:“Patients are among their own best advocates. They aggressively pursue what is in development.” https://t.co/YxeQtdTzBI

[Pulmatrix @Pulmatrix_Inc]

$PULM CSO David Hava: “Our goal is to identify a PUR0200 candidate to advance to a pivotal PK bioequivalence trial” https://t.co/LYyBEVWD3S

[Pulmatrix @Pulmatrix_Inc]

$PULM featured in @PharmaVOICE: Patients and Patient Organizations Power Rare Disease Therapies https://t.co/lLZY8nRUr9

[Pulmatrix @Pulmatrix_Inc]

$PULM Initiates European Pilot Bioequivalence Study of PUR0200 for COPD: https://t.co/MKMl4sWGh8

[Pulmatrix @Pulmatrix_Inc]

$PULM's iSPERSE technology is flow rate independent, providing reliable dose delivery across patient populations. https://t.co/UpEVNh2MUr

[Pulmatrix @Pulmatrix_Inc]

$PULM's PUR1900 is an inhaled drug which inhibits fungal growth in Cystic Fibrosis #JPM16

[Pulmatrix @Pulmatrix_Inc]

$PULM's ISPERSE platform enables efficient lung delivery with high drug loads #JPM16

[Pulmatrix @Pulmatrix_Inc]

$PULM pipeline: PUR 0200 for COPD, PUR1900 for Cystic Fibrosis, PUR1500 for Idiopathic Pulmonary Fibrosis #JPM16

[healtheo360® @healtheo360]

Robert Clarke of Plumatrix - pipeline inhaled therapies for #COPD #CysticFibrosis #realstories @russopartners #JPM16

[David Schull @davidschull]

@GENbio @Pulmatrix_Inc $PULM #jpm16 We can make inhaled formulations of any drug. GEN technology to watch at JPMorgan

[Pulmatrix @Pulmatrix_Inc]

$PULM to Present at Upcoming Investor Conferences: https://t.co/RiO2ViY0EI

[Pulmatrix @Pulmatrix_Inc]

$PULM to list on Nasdaq Global Market. https://t.co/3wXjxFC1jp

[Pulmatrix @Pulmatrix_Inc]

$PULM's iSPERSE drug platform provides reliable dose delivery across patient populations https://t.co/YH7QDLDCia

[Pulmatrix @Pulmatrix_Inc]

$PULM inhaled antifungal drug in development for #CysticFibrosis demonstrated high lung retention in study. https://t.co/FdyjDF1rbu

[Pulmatrix @Pulmatrix_Inc]

$PULM appoints Mark Iwicki chairman of the board. https://t.co/K8kNOkjyEk